Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Singular Genomics Systems, Inc. | omic-20210630ex32_1.htm |
EX-31.2 - EX-31.2 - Singular Genomics Systems, Inc. | omic-20210630ex31_2.htm |
EX-31.1 - EX-31.1 - Singular Genomics Systems, Inc. | omic-20210630ex31_1.htm |
10-Q - 10-Q - Singular Genomics Systems, Inc. | omic-20210630.htm |
Exhibit 32.2
CERTIFICATIONS OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Singular Genomics Systems, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dalen Meeter, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: August 2, 2021 |
|
By: |
/s/ Dalen Meeter |
|
|
|
Dalen Meeter |
|
|
|
Senior Vice President, Finance (Principal Financial Officer and Principal Accounting Officer) |